IL108285A0 - Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes - Google Patents

Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes

Info

Publication number
IL108285A0
IL108285A0 IL10828594A IL10828594A IL108285A0 IL 108285 A0 IL108285 A0 IL 108285A0 IL 10828594 A IL10828594 A IL 10828594A IL 10828594 A IL10828594 A IL 10828594A IL 108285 A0 IL108285 A0 IL 108285A0
Authority
IL
Israel
Prior art keywords
riluzole
parkinson
disease
treatment
pct
Prior art date
Application number
IL10828594A
Other languages
English (en)
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of IL108285A0 publication Critical patent/IL108285A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
IL10828594A 1993-01-07 1994-01-06 Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes IL108285A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300074A FR2700117B1 (fr) 1993-01-07 1993-01-07 Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.

Publications (1)

Publication Number Publication Date
IL108285A0 true IL108285A0 (en) 1994-04-12

Family

ID=9442862

Family Applications (3)

Application Number Title Priority Date Filing Date
IL10828694A IL108286A0 (en) 1993-01-07 1994-01-06 Use of anticonvulsants in the treatment of parkinson's disease and parkinsonian syndromes
IL10828594A IL108285A0 (en) 1993-01-07 1994-01-06 Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
IL10828494A IL108284A (en) 1993-01-07 1994-01-06 Pharmaceutical preparations containing rilosol for the treatment of Parkinson's disease and Parkinson's syndromes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL10828694A IL108286A0 (en) 1993-01-07 1994-01-06 Use of anticonvulsants in the treatment of parkinson's disease and parkinsonian syndromes

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL10828494A IL108284A (en) 1993-01-07 1994-01-06 Pharmaceutical preparations containing rilosol for the treatment of Parkinson's disease and Parkinson's syndromes

Country Status (23)

Country Link
US (2) US5674885A (es)
EP (2) EP0678026B1 (es)
JP (2) JPH08505379A (es)
KR (2) KR100298807B1 (es)
AT (2) ATE141792T1 (es)
AU (3) AU684059B2 (es)
CA (2) CA2153340C (es)
CZ (2) CZ284363B6 (es)
DE (2) DE69400799T2 (es)
DK (2) DK0678023T3 (es)
ES (2) ES2092890T3 (es)
FR (1) FR2700117B1 (es)
GR (2) GR3020975T3 (es)
HU (2) HU217136B (es)
IL (3) IL108286A0 (es)
MX (2) MX9307885A (es)
NO (2) NO307495B1 (es)
PL (2) PL309596A1 (es)
RU (1) RU2221563C2 (es)
SK (2) SK279758B6 (es)
UA (1) UA29464C2 (es)
WO (3) WO1994015607A1 (es)
ZA (3) ZA9428B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6119094A (en) * 1996-02-29 2000-09-12 Electronic Data Systems Corporation Automated system for identifying alternate low-cost travel arrangements
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
AU1780699A (en) * 1998-01-09 1999-07-26 Mor Research Applications Ltd. Treatment of dyskinesias
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6506378B1 (en) * 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
FR2801793B1 (fr) * 1999-12-01 2003-07-04 Aventis Pharma Sa Association d'une ergoline et de riluzole et son utilisation comme medicament
DE02718948T1 (de) * 2001-02-12 2004-07-08 Teva Pharmaceutical Industries Ltd. Neue kristallformen von oxcarbazepin und verfahren zu deren herstellung
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
WO2005037276A1 (en) * 2003-10-09 2005-04-28 Aventis Pharma S.A. Use of riluzole for the treatment of essential tremor
CA2471666C (en) * 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
EP1924326B1 (en) 2005-08-25 2016-10-12 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
CA2597740C (en) * 2006-04-26 2012-10-16 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
JP2010539123A (ja) * 2007-09-14 2010-12-16 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 変性疾患の処置のための神経内分泌因子
EP3006024B1 (en) 2009-01-20 2019-03-20 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Benzoic acid or salts thereof to enhance the activity of a neuropharmaceutical
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
RU2022101542A (ru) 2016-06-13 2022-02-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
MX2018015397A (es) 2016-06-13 2019-08-16 Syneurx Int Taiwan Corp Co-cristales de benzoato de sodio y sus usos.
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
US11439626B2 (en) 2019-09-20 2022-09-13 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.

Also Published As

Publication number Publication date
ATE144420T1 (de) 1996-11-15
JPH08505378A (ja) 1996-06-11
FR2700117A1 (fr) 1994-07-08
MX9400287A (es) 1994-07-29
NO952310D0 (no) 1995-06-12
ATE141792T1 (de) 1996-09-15
NO952309D0 (no) 1995-06-12
HU9502063D0 (en) 1995-09-28
CZ284363B6 (cs) 1998-11-11
CA2153340C (fr) 2002-12-17
ZA9432B (en) 1994-08-11
HUT72074A (en) 1996-03-28
GR3020975T3 (en) 1996-12-31
NO952310L (no) 1995-06-12
FR2700117B1 (fr) 1995-02-03
DK0678023T3 (da) 1996-11-25
JP3120153B2 (ja) 2000-12-25
IL108284A0 (en) 1994-04-12
WO1994015607A1 (fr) 1994-07-21
US5658900A (en) 1997-08-19
IL108286A0 (en) 1994-04-12
CZ176495A3 (en) 1995-12-13
ZA9426B (en) 1994-08-11
GR3021438T3 (en) 1997-01-31
AU684059B2 (en) 1997-12-04
SK279758B6 (sk) 1999-03-12
DE69400435D1 (de) 1996-10-02
EP0678026A1 (fr) 1995-10-25
CZ176595A3 (en) 1995-12-13
HU217136B (hu) 1999-11-29
AU5818994A (en) 1994-08-15
ES2091689T3 (es) 1996-11-01
NO952309L (no) 1995-06-12
EP0678023B1 (fr) 1996-10-23
US5674885A (en) 1997-10-07
CA2153341A1 (fr) 1994-07-21
ES2092890T3 (es) 1996-12-01
AU5818894A (en) 1994-08-15
RU2221563C2 (ru) 2004-01-20
NO307495B1 (no) 2000-04-17
KR100298807B1 (ko) 2001-11-22
MX9307885A (es) 1994-07-29
HU9502065D0 (en) 1995-09-28
DE69400799D1 (de) 1996-11-28
PL309596A1 (en) 1995-10-30
DK0678026T3 (da) 1996-09-16
SK86795A3 (en) 1995-11-08
DE69400435T2 (de) 1997-03-06
AU5819094A (en) 1994-08-15
AU677279B2 (en) 1997-04-17
DE69400799T2 (de) 1997-03-13
KR960700059A (ko) 1996-01-19
WO1994015601A1 (fr) 1994-07-21
KR960700054A (ko) 1996-01-19
EP0678023A1 (fr) 1995-10-25
ZA9428B (en) 1994-08-11
WO1994015610A1 (fr) 1994-07-21
IL108284A (en) 1999-03-12
CZ284928B6 (cs) 1999-04-14
JPH08505379A (ja) 1996-06-11
PL309594A1 (en) 1995-10-30
UA29464C2 (uk) 2000-11-15
HUT72328A (en) 1996-04-29
EP0678026B1 (fr) 1996-08-28
SK86695A3 (en) 1996-05-08
SK279645B6 (sk) 1999-01-11
CA2153340A1 (fr) 1994-07-21

Similar Documents

Publication Publication Date Title
IL108284A0 (en) Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
ZA9427B (en) Use of riluzole for promoting restoration following radiation